Facial cosmetic filler injections as possible target for systemic sarcoidosis in patients treated with interferon for chronic hepatitis C: two cases.
BACKGROUND
Cosmetic filler injections are now a very common procedure for aesthetic purposes. Today no contra-indication is given anymore to any patient for an intradermal filling.


OBJECTIVE
We draw attention to a possible side effect of facial fillers in a population at risk.


RESULTS
We report 2 similar cases of systemic sarcoidosis in patients who both developed a sarcoidal granuloma at the location of a cosmetic filler injection during combined interferon and ribavirin treatment for chronic hepatitis C infection. Cosmetic fillers were hyaluronic acid for one patient and probably silicone for the other.


CONCLUSIONS
Patients with chronic hepatitis C have a higher risk of interferon-induced sarcoidosis. Physicians must be aware of the risk that a granuloma can develop after a dermal filler injection especially in patients treated with interferon for chronic hepatitis C. These reactions may reveal a systemic sarcoidosis. We propose to perform a test for a hepatitis C virus infection before injecting a dermal filler and to inform the patient of this risk in case of a hepatitis C infection that could necessitate an interferon treatment.
Descamps
Vincent
V
Department of Dermatology, Bichat Claude Bernard Hospital, Paris, France. vincent.descamps@bch.aphp.fr
Landry
Jennifer
J
Francès
Camille
C
Marinho
Eduardo
E
Ratziu
Vlad
V
Chosidow
Olivier
O
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000009:adverse effects*; D003357:Cosmetic Techniques / Q000009:adverse effects*; D005260:Female; D006099:Granuloma / Q000139:chemically induced / Q000473:pathology; D006526:Hepatitis C / Q000188:drug therapy; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000009:adverse effects*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012507:Sarcoidosis / Q000139:chemically induced* / Q000473:pathology; D017565:Sarcoidosis, Pulmonary / Q000139:chemically induced; D012828:Silicones / Q000008:administration & dosage / Q000009:adverse effects; D012867:Skin / Q000473:pathology; D012871:Skin Diseases / Q000139:chemically induced / Q000473:pathology
D000998:Antiviral Agents; D001672:Biocompatible Materials; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012828:Silicones; D011092:Polyethylene Glycols; D012254:Ribavirin; D006820:Hyaluronic Acid; C417083:peginterferon alfa-2b